https://www.selleckchem.com/products/tmp195.html
9% vs. 0%; P less then .0001 for complete response), and month 6 (87.5% vs. 5.9%; P less then .0001 for response; 81.3% vs. 5.9%; P less then .0001 for complete response). Durable responders from the core study achieved response and complete response at 96.1% and 60.1% of extension phase visits, respectively. Durable clinically relevant response (Plt ≥30 000/µL for 6 of the final 8 weeks of the core study) occurred in 64.0% of avatrombopag-treated patients versus 0% of placebo-treated patients. More than half (57.1%) of patients on chron
Like
Comment
Share
